03:49 PM EST - Lorus Therapeutics Inc : announced it will present preclinical data for LOR-253 in acute myeloid leukemia and other hematologic cancers at the American Association for Cancer Research Annual Meeting 2014, to be held at the San Diego Convention Center in San Diego, CA, April 5-9. LOR-253, the company's lead anti-cancer agent, is a clinical-stage, small molecule therapeutic that acts through induction of the innate tumor suppressor Krüppel-like factor 4. Lorus Therapeutics Inc
shares T.LOR are trading down $0.01 at $0.50.
